Table 2. Clinicopathological features of the autopsy cohort of 13 patients who were positive for SARS-CoV-2.

Patient	1	2	3	4	5	6	7	8	9	10	11	12	13
Age	41	78	80	81	90	84	79	82	60	71	76	76	72
Sex	m	m	m	f	f	m	m	m	m	m	f	m	m
Body-mass index	29.0	23.4	23.2	30.0	28.2	26.2	26.3	24.4	27.8	24.3	20.7	27.1	36.5
NIcotine abuse	n. b.	Ø	Ø	n. b.	n. b.	n. b.	Ø	Z. n.	n. b.	Ø	n. b.	n. b.	Z. n.
Comorbidity	FLD	Ø	S/p PCA (2004)	AH, COPD, MetS	AH, DM, MetS, CRF	CHD	AH, DM, CHD, DCMP	AH, COPD, CHD	AH, AS	CHD	AH, DM	AH, DM, CHD	AH, DM, CHD, MetS, CRF
Duration of disease (days)	12	16	7	6	12	22	23	32	27	34	33	40	32
Time to diagnosis (days)	11	0	6	4	2	13	14	1	0	3	0	7	10
Length of hospital stay (days)	2	12	1	3	10	9	9	28	27	30	24	33	19
Pathogens revealed by BAL	Ø	Ps. ae.	Ø	Ø	Ø	Ø	Ø	Ps. ae.	Ø	Ø	Ø	Ø	Ps. ae.
Mechanical ventilation (days)	refused	12	Ø	refused	refused	7	8	6	20	15	24	31	22
Drug treatment	AB	AB, IMT, FH	Ø	AB, IMT	AB, IMT	AB, IMT, FH	AB, IMT, FH	AB, IMT, PA	AB, IMT, PA, TNFi	AB, AV, IMT, FH	AB, IMT, FH	AB, AV, IMT, VH	AB, AV, IMT, VH
D-dimers (< 0.5 mg/l)	n.a.	>35	n.a.	>35	6.03	> 35	> 35	1.17	15.3	19.9	5.07	21.6	3.41
Cause of death	CPF	PF	CPF	CPF	CPF	PF	PF	IB	PF	PF	PF	CPF	PF

AB, antibiotics (piperacillin/tazobactam/caspofungin); AH, arterial hypertension; AS, ankylosing spondylitis (Bekhterev’s disease); AV, antiviral therapy (aciclovir); BAL, bronchioalveolar lavage; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CPF, cardiopulmonary failure; CRF, chronic renal failure; DCMP, dilated cardiomyopathy; DM, type 2 diabetes mellitus; f, female; FH, full heparainization (1 000 IU heparin/h); FLD, fatty liver disease; IB, intestinal bleed; IMT, immune-modulating treatment (hydroxychloroquine/maraviroc); MetS, metabolic syndrome; m, male; n. a., data not availablet; PA, prophylactic anticoagulation (enoxaparin 40 mg b.i.d.); PCA, prostatic carcinoma; PF, pulmonary failure; Ps. ae., Pseudomonas aeruginosa; S/p, status post; TNFi,anti-tumor necrosis factor α antibodies (golimumab).